Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDRiver Solid Tumors 301: M1774 in Advanced Solid Tumors
jRCT2031220326Phase 1Active, not recruiting
- Sponsor
- Merck KGaA
- Start
- Sep 2022
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of tuvusertib in Nonhematologic neoplasms (4 cohorts), sponsored by Merck KGaA. Primary endpoints: Dose-limiting toxicities in Part A4, Safety and tolerability in Part A4 and 9 more. Started Sep 2022; status: active, not recruiting.
02
Drugs
tuvusertib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031220326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220326.